DK0666912T3 - Modificerede ciliære neurotiske faktorer - Google Patents
Modificerede ciliære neurotiske faktorerInfo
- Publication number
- DK0666912T3 DK0666912T3 DK93923333.4T DK93923333T DK0666912T3 DK 0666912 T3 DK0666912 T3 DK 0666912T3 DK 93923333 T DK93923333 T DK 93923333T DK 0666912 T3 DK0666912 T3 DK 0666912T3
- Authority
- DK
- Denmark
- Prior art keywords
- factors
- modified ciliary
- neurotic
- modified
- ciliary neurotic
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/959,284 US5349056A (en) | 1992-10-09 | 1992-10-09 | Modified ciliary neurotrophic factors |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0666912T3 true DK0666912T3 (da) | 1997-09-29 |
Family
ID=25501875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK93923333.4T DK0666912T3 (da) | 1992-10-09 | 1993-10-08 | Modificerede ciliære neurotiske faktorer |
Country Status (14)
Country | Link |
---|---|
US (5) | US5349056A (da) |
EP (1) | EP0666912B1 (da) |
JP (1) | JP2702811B2 (da) |
AT (1) | ATE151460T1 (da) |
AU (1) | AU667996B2 (da) |
CA (1) | CA2132954C (da) |
DE (1) | DE69309702T2 (da) |
DK (1) | DK0666912T3 (da) |
ES (1) | ES2099981T3 (da) |
GR (1) | GR3024039T3 (da) |
HK (1) | HK1007767A1 (da) |
IL (1) | IL107213A0 (da) |
WO (1) | WO1994009134A2 (da) |
ZA (1) | ZA937482B (da) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5141856A (en) * | 1989-01-05 | 1992-08-25 | Synergen, Inc. | Expression of purified ciliary neurotrophic factor |
US6472178B1 (en) * | 1998-02-27 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof |
US5349056A (en) * | 1992-10-09 | 1994-09-20 | Regeneron Pharmaceuticals | Modified ciliary neurotrophic factors |
DK0632008T3 (da) * | 1993-06-01 | 1998-09-23 | Ono Pharmaceutical Co | Pentansyrederivater |
AU1282895A (en) * | 1993-12-29 | 1995-07-17 | Sumitomo Pharmaceuticals Company, Limited | Novel human ciliary neurotrophic factor |
WO1997012635A1 (en) * | 1995-10-02 | 1997-04-10 | Cytotherapeutics, Inc. | Method for treating amyotrophic lateral sclerosis |
US5859311A (en) * | 1995-11-27 | 1999-01-12 | University Of Kentucky Research Foundation | Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use |
IT1284867B1 (it) * | 1996-07-10 | 1998-05-22 | Angeletti P Ist Richerche Bio | Varianti del fattore neurotrofico ciliare umano (hcntf) con uno spettro di azione differente dalla molecola di tipo selvatico |
BR9712824A (pt) * | 1996-09-13 | 1999-12-21 | Advanced Medicine Research Ins | Composição oftálmica de fator neurotrófico, agente de tratamento de desordem funcional do nervo ótico e método para tratamento de desordem funcional do nervo ótico |
IT1288388B1 (it) * | 1996-11-19 | 1998-09-22 | Angeletti P Ist Richerche Bio | Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia |
US20040120891A1 (en) * | 1998-12-21 | 2004-06-24 | Craig Hill | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
JP2003507393A (ja) * | 1999-08-13 | 2003-02-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 改変された毛様体神経栄養因子、それらを作製する方法およびそれらの使用方法 |
US7442370B2 (en) * | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
AU2002253942A1 (en) * | 2001-02-12 | 2002-08-28 | Michael Amling | Methods and compositions for control of bone formation via modulation of ciliary neurotrophic factor activity |
US7276580B2 (en) * | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
IL162269A0 (en) | 2001-12-05 | 2005-11-20 | Baylor College Medicine | Methods and compositions for control of bone formation via modulation of sympathetic tone |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
AU2003275846A1 (en) * | 2002-10-24 | 2004-05-13 | The University Of British Columbia | Methods for neuroprotection |
JP4571776B2 (ja) * | 2002-11-05 | 2010-10-27 | Jx日鉱日石エネルギー株式会社 | 潤滑油組成物 |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP1897552B1 (en) | 2003-04-18 | 2009-06-17 | Biogen Idec MA Inc. | Polymer-conjugated glycosylated neublastin |
GEP20084406B (en) | 2003-05-30 | 2008-06-25 | Ranbaxy Lab Ltd | Substituted pyrrole derivatives and their use as hmg-co inhibitors |
WO2005014641A2 (en) * | 2003-07-09 | 2005-02-17 | Xencor, Inc. | Ciliary neurotrophic factor variants |
JP4765627B2 (ja) | 2003-09-22 | 2011-09-07 | Msd株式会社 | 新規ピペリジン誘導体 |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
CN102924585A (zh) * | 2004-08-19 | 2013-02-13 | 比奥根艾迪克Ma公司 | 神经胚素变体 |
WO2006023782A2 (en) | 2004-08-19 | 2006-03-02 | Biogen Ideca Ma Inc. | Refolding transforming growth factor beta family proteins |
US20090156474A1 (en) | 2004-11-01 | 2009-06-18 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity and obesity related diseases and disorders |
US20060178301A1 (en) * | 2005-02-04 | 2006-08-10 | Mathias Jurs | Albumin-fused ciliary neurotrophic factor |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
AU2006253312B2 (en) | 2005-05-30 | 2011-08-18 | Msd K.K. | Novel piperidine derivative |
US20100216758A1 (en) | 2005-08-10 | 2010-08-26 | Makoto Ando | Pyridone Compounds |
CA2619770A1 (en) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
WO2007029847A1 (ja) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | 二環性芳香族置換ピリドン誘導体 |
JP4879988B2 (ja) | 2005-09-29 | 2012-02-22 | メルク・シャープ・エンド・ドーム・コーポレイション | メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体 |
CN101291662A (zh) | 2005-10-21 | 2008-10-22 | 诺瓦提斯公司 | 肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合 |
JPWO2007049798A1 (ja) | 2005-10-27 | 2009-04-30 | 萬有製薬株式会社 | 新規ベンゾオキサチイン誘導体 |
AU2006313430B2 (en) | 2005-11-08 | 2012-09-06 | Ranbaxy Laboratories Limited | Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
AU2006312557B2 (en) | 2005-11-10 | 2011-12-08 | Msd K.K. | Aza-substituted spiro derivative |
JP2009525319A (ja) * | 2006-02-02 | 2009-07-09 | ライナット ニューロサイエンス コーポレイション | trkBアンタゴニストを投与することにより肥満を治療する方法 |
NL2000464C2 (nl) * | 2006-02-02 | 2007-09-11 | Rinat Neuroscience Corp | Werkwijzen voor het behandelen van ongewenst gewichtsverlies of eetstoornissen door het toedienen van een TRKB-agonist. |
TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
EP1993590B1 (en) * | 2006-03-01 | 2013-12-25 | Biogen Idec MA Inc. | Compostions and methods for administering gdnf ligand family proteins |
EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
CA2664358A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diarylketimine derivative |
BRPI0720473A2 (pt) * | 2006-12-20 | 2014-01-14 | Rinat Neuroscience Corp | Agonistas de trkb para tratamento de distúbios autoimunes |
EP2145884B1 (en) | 2007-04-02 | 2014-08-06 | Msd K.K. | Indoledione derivative |
ES2476253T3 (es) | 2007-05-01 | 2014-07-14 | Biogen Idec Ma Inc. | P�ptidos de neublastina para su uso en el aumento de la vascularizaci�n en tejido con flujo sanguíneo deteriorado |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US20100120694A1 (en) | 2008-06-04 | 2010-05-13 | Synergy Pharmaceuticals, Inc. | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders |
EP2205634A2 (en) * | 2007-08-08 | 2010-07-14 | Biogen Idec MA, Inc. | Anti-neublastin antibodies and uses thereof |
WO2009079837A1 (fr) * | 2007-12-18 | 2009-07-02 | Hangzhou Jiuyuan Gene Engineering Co., Ltd. | Formulation pharmaceutique contenant une protéine de fusion sérum albumine humaine recombinante-interféron alpha |
JPWO2009110510A1 (ja) | 2008-03-06 | 2011-07-14 | Msd株式会社 | アルキルアミノピリジン誘導体 |
JPWO2009119726A1 (ja) | 2008-03-28 | 2011-07-28 | Msd株式会社 | メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体 |
US20110071129A1 (en) | 2008-06-19 | 2011-03-24 | Makoto Ando | Spirodiamine-diaryl ketoxime derivative |
EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2010013595A1 (ja) | 2008-07-30 | 2010-02-04 | 萬有製薬株式会社 | 5員-5員又は5員-6員縮環シクロアルキルアミン誘導体 |
EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
MX348131B (es) | 2011-02-25 | 2017-05-26 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos. |
US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US9840512B2 (en) | 2013-02-22 | 2017-12-12 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
ES2901114T3 (es) | 2014-08-29 | 2022-03-21 | Tes Pharma S R L | Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa |
KR20190065312A (ko) | 2016-10-14 | 2019-06-11 | 테스 파마 에스.알.엘. | 알파-아미노-베타-카복시뮤콘산 세미알데하이드 데카복실라제의 저해제 |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
JP2021530507A (ja) | 2018-07-18 | 2021-11-11 | マンザニータ ファーマシューティカルズ,インク. | 神経細胞に抗がん剤を送達するためのコンジュゲート、その使用方法及び製造方法 |
WO2020104456A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US4997929A (en) * | 1989-01-05 | 1991-03-05 | Synergen, Inc. | Purified ciliary neurotrophic factor |
KR910016921A (ko) * | 1990-03-14 | 1991-11-05 | 파디아 에스. 피. 에이 | 인간의 모양체 신경원영양 인자, 그를 코딩하는 dna 서열 및 재조합 기술에 의한 그의 제조방법 |
JPH07500725A (ja) * | 1991-07-23 | 1995-01-26 | シンテックス−シナージェン ニューロサイエンス ジョイント ベンチャー | 組換え毛様体向神経因子およびc−末端切断毛様体向神経因子の精製ならびに末梢神経障害の処置方法 |
US5593857A (en) * | 1991-08-23 | 1997-01-14 | Scios Inc. | Production of homogeneous truncated CNTF |
US5349056A (en) * | 1992-10-09 | 1994-09-20 | Regeneron Pharmaceuticals | Modified ciliary neurotrophic factors |
-
1992
- 1992-10-09 US US07/959,284 patent/US5349056A/en not_active Expired - Lifetime
-
1993
- 1993-10-08 EP EP93923333A patent/EP0666912B1/en not_active Expired - Lifetime
- 1993-10-08 AT AT93923333T patent/ATE151460T1/de active
- 1993-10-08 IL IL107213A patent/IL107213A0/xx unknown
- 1993-10-08 ES ES93923333T patent/ES2099981T3/es not_active Expired - Lifetime
- 1993-10-08 DE DE69309702T patent/DE69309702T2/de not_active Expired - Lifetime
- 1993-10-08 AU AU53260/94A patent/AU667996B2/en not_active Ceased
- 1993-10-08 WO PCT/US1993/009649 patent/WO1994009134A2/en active IP Right Grant
- 1993-10-08 CA CA002132954A patent/CA2132954C/en not_active Expired - Fee Related
- 1993-10-08 ZA ZA937482A patent/ZA937482B/xx unknown
- 1993-10-08 JP JP6510157A patent/JP2702811B2/ja not_active Expired - Fee Related
- 1993-10-08 DK DK93923333.4T patent/DK0666912T3/da active
-
1994
- 1994-09-19 US US08/308,736 patent/US5846935A/en not_active Expired - Lifetime
-
1997
- 1997-07-09 GR GR970401694T patent/GR3024039T3/el unknown
-
1998
- 1998-06-26 HK HK98106965A patent/HK1007767A1/xx not_active IP Right Cessation
- 1998-11-20 US US09/197,349 patent/US6440702B1/en not_active Expired - Fee Related
-
2002
- 2002-08-23 US US10/226,759 patent/US20030092129A1/en not_active Abandoned
-
2003
- 2003-03-07 US US10/383,916 patent/US20030220484A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2099981T3 (es) | 1997-06-01 |
EP0666912B1 (en) | 1997-04-09 |
CA2132954A1 (en) | 1994-04-28 |
WO1994009134A2 (en) | 1994-04-28 |
IL107213A0 (en) | 1994-01-25 |
AU5326094A (en) | 1994-05-09 |
EP0666912A1 (en) | 1995-08-16 |
DE69309702D1 (de) | 1997-05-15 |
AU667996B2 (en) | 1996-04-18 |
HK1007767A1 (en) | 1999-04-23 |
ATE151460T1 (de) | 1997-04-15 |
US5349056A (en) | 1994-09-20 |
DE69309702T2 (de) | 1997-10-30 |
GR3024039T3 (en) | 1997-10-31 |
WO1994009134A3 (en) | 1994-05-26 |
US20030220484A1 (en) | 2003-11-27 |
US20030092129A1 (en) | 2003-05-15 |
US5846935A (en) | 1998-12-08 |
JP2702811B2 (ja) | 1998-01-26 |
ZA937482B (en) | 1994-04-26 |
CA2132954C (en) | 2000-01-18 |
US6440702B1 (en) | 2002-08-27 |
JPH07506005A (ja) | 1995-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0666912T3 (da) | Modificerede ciliære neurotiske faktorer | |
DE69431285T2 (de) | Herstellungsmethode von markierten genen; transcripten und proteinen | |
DE69435262D1 (de) | Herstellungsverfahren von Elektroden | |
ES546654A0 (es) | Metodo de produccion de factor viii:c humano | |
IT9020763A0 (it) | metodo per formare | |
ATE112802T1 (de) | Herstellung von funktionellen menschlichen urokinasepolypeptiden. | |
FI98149B (fi) | Menetelmä ja laite suspensioiden fraktioimiseksi | |
DE68929060T2 (de) | Synthese von 1,2-Dioxetanen und Zwischenprodukte dafür | |
DE69001551D1 (de) | Latexfilme von naturkautschuk von modifizierter zugfestigkeit. | |
DE68918245D1 (de) | Verfahren zum Herstellen von Schmuckstücken. | |
NO960455D0 (no) | Foranderlig blanding og fremgangsmåte for anvendelse av denne | |
ES2123582T3 (es) | Proteina con capacidad de formacion de huesos y procedimiento para su produccion. | |
DK538286D0 (da) | Humanlysozym | |
DE3777097D1 (de) | Herstellungsverfahren von tert.-butylmethacrylat. | |
DK398987D0 (da) | Fremgangsmaade til fremstilling af blodprotein | |
ES2135477T3 (es) | Proceso de produccion de (s)-3-amino-1-pirrolidinas sustituidas. | |
DE68910395D1 (de) | Verfahren zur Herstellen von Kolbenringen. | |
KR880005263A (ko) | 단백질의 신규제법 | |
BR8506371A (pt) | Processo de producao de polissacarideos por fermentacao e emulsoes de oleo-em-agua | |
DE3671346D1 (de) | Verfahren zur frequenzsynthese und dieses verfahren verwendendes synthesierergeraet. | |
DK75393D0 (da) | Production of protein | |
DE58908855D1 (de) | Verfahren zur Herstellung von Gate-Elektroden. | |
DE69318270D1 (de) | Verfahren zum Herstellen von Scharnieren | |
GR900100615A (el) | Νεοι υποκατεστημενοι ετεροκυκλικοι δακτυλιοι πεντανιου,παραγωγη και χρησις αυτων. | |
ATE210605T1 (de) | Verwendung von sulfonamiden zur kontrolle von biobewuchs |